Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04626674 · ClinicalTrials.gov registry record · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
A Phase 1 study of Muscular Dystrophy, Duchenne, sponsored by Sarepta Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
- 5
- Study locations
NCT04626674 is a Phase 1 study of Muscular Dystrophy, Duchenne that is actively recruiting participants, run by Sarepta Therapeutics. The registered enrollment target is 83 participants, roughly in line with the 87-participant average among 4 other Muscular Dystrophy, Duchenne trials with a reported enrollment target. The trial reports 5 study locations across 4 states.
The verdict
NCT04626674, a Phase 1 study of Muscular Dystrophy, Duchenne, is actively recruiting participants, sponsored by Sarepta Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with DMD. The maximum participant duration for this study is 156 weeks.
Conditions Studied
Interventions
- GENETIC delandistrogene moxeparvovec
Study Locations (5)
California
- Stanford University - Palo Alto
- University of California, Davis - Sacramento
Missouri
- Washington University in St. Louis - St Louis
Ohio
- Nationwide Children's Hospital - Columbus
Virginia
- Children's Hospital of The King's Daughters - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2028-02-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04626674
The ClinicalTrials.gov registry entry for NCT04626674 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 87-participant average among 4 other Muscular Dystrophy, Duchenne trials with a reported enrollment target. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscular Dystrophy, Duchenne appearing as the primary indexed condition, and to 1 intervention - of which delandistrogene moxeparvovec is the first listed.
NCT04626674 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT04626674 about?
NCT04626674 is a clinical study titled "A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)". This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with DMD. The maximum participant duration for this study is 156 weeks.
What is the current status of trial NCT04626674?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2020-11-23. Estimated completion is 2028-02-29.
What conditions does trial NCT04626674 study?
This clinical trial studies the following conditions: Muscular Dystrophy, Duchenne.
What interventions are being tested in trial NCT04626674?
The interventions under investigation include: delandistrogene moxeparvovec (GENETIC).
Who is sponsoring clinical trial NCT04626674?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04626674 being conducted?
This trial has 5 study locations across California, Missouri, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscular Dystrophy, Duchenne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)
COMPLETED · Phase 1
-
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.